Search clinical trials for: SyB P-1501 placebo

Total 1987 results

SymBio Pharmaceuticals

Terminated

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Postoperative Pain

Japan
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Japan
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Myelodysplastic Syndrome

Japan
VBI Vaccines Inc.
Clinical Trial Data Services, LLC

Completed

Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

Canada
SymBio Pharmaceuticals

Completed

Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)

Radiotherapy-induced Nausea and Vomiting (RINV)

Japan
SymBio Pharmaceuticals

Recruiting

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

BK Virus Infection | Kidney Transplantation | Nephropathy

Australia, Japan
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
GlaxoSmithKline

Completed

Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)

Multiple Sclerosis

Italy, Germany, Spain, United Kingdom, Australia, Netherlands, New Zealand, Russian Federation, France, Canada, Austria, Poland, Finland, Norway
SN BioScience

Not yet recruiting

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Small-cell Lung Cancer | Pancreas Cancer

Korea, Republic of
Aminex Therapeutics, Inc.
Iqvia Pty Ltd; Novella Clinical

Withdrawn

Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers

Neoplasms | Tolerance | Medication Toxicity

United States
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Low-grade B Cell Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated

Japan
SymBio Pharmaceuticals

Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Japan
Poseida Therapeutics, Inc.

Active, not recruiting

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Neoplasms | Neoplasms by Histologic Type | Urogenital Neoplasms | Neoplasms by Site | Genital Neoplasms, Male | Prostatic Neoplasms | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Prostate Cancer | Prostatic Neoplasms, Castration-Resistant | Metastatic Castration-resistant Prostate Cancer | Neoplasms... and other conditions

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Hoffmann-La Roche

Completed

PRM-151 in the Prevention of Scarring Following Trabeculectomy

Glaucoma

United Kingdom, Belgium, Czechia, Netherlands
Symbiomix Therapeutics

Completed

A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

Bacterial Vaginosis

United States
CellabMED
Yooyoung Pharmaceutical Co., Ltd.

Completed

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Colorectal Cancer Metastatic | Colorectal Cancer Recurrent

Korea, Republic of
Synthetic Biologics Inc.

Completed

A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI

Clostridium Infections | Clostridium Difficile

United States, Bulgaria, Canada, Hungary, Poland, Romania, Serbia
Synthetic Biologics Inc.

Completed

A Study of the Effect of SYN-010 on Subjects With IBS-C

Irritable Bowel Syndrome With Constipation (IBS-C)

United States
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
Maastricht University Medical Center

Completed

Bio-equivalence Study

Bioavailability | Bioequivalence

Netherlands
CellabMED

Completed

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Solid Tumors

Korea, Republic of
University of Chicago
Asphelia Pharmaceuticals

Completed

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

Allergic Rhinitis

United States
Kineta Inc.

Completed

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

Healthy

United States
Larimar Therapeutics, Inc.
Veristat, Inc.; Metrum Research Group, LLC

Completed

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Friedreich Ataxia

United States
Respivant Sciences GmbH
Respivant Sciences Inc.

Terminated

A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF (SCENIC)

Chronic Cough | IPF | Persistent Cough in IPF

United States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
Cyclerion Therapeutics

Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Healthy

United States
HemaQuest Pharmaceuticals Inc.

Completed

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

Sickle Cell Disease

United States, Jamaica
Larimar Therapeutics, Inc.

Completed

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Friedreich Ataxia

United States
Avidity Biosciences, Inc.

Completed

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (MARINA)

Myotonic Dystrophy | Myotonic Disorders | Myotonic Dystrophy Type 1 (DM1) | Myotonic Dystrophy 1 | Myotonic Muscular Dystrophy | DM1 | Dystrophy Myotonic | Steinert Disease

United States
Immunovant Sciences GmbH

Completed

A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Myasthenia Gravis

United States, Canada
Circadian Therapeutics Ltd
Neuroscience Trials Australia

Completed

First in Human Study of CT-1500 in Healthy Participants

Healthy

Australia
Bayer

Completed

Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis

Bronchiectasis

Italy, Spain, Germany, United Kingdom, France
Viriom

Completed

Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers

HIV-infection

Russian Federation
HemaQuest Pharmaceuticals Inc.

Terminated

Effects of HQK-1001 in Patients With Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin S

United States, Lebanon, Egypt, Canada, Jamaica
HemaQuest Pharmaceuticals Inc.

Completed

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

Healthy

United States
Curacle Co., Ltd.

Recruiting

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Diabetic Nephropathies

Korea, Republic of
Larimar Therapeutics, Inc.
Veristat, Inc.; Metrum Research Group, LLC

Completed

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Friedreich Ataxia

United States
TRF Pharma, Inc

Terminated

TRF-1101 Assessment in Sickle Cell Disease

Sickle Cell Disease

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Brigham and Women's Hospital

Recruiting

CP101 for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Takeda

Completed

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease

Type 2 Diabetes Mellitus

Japan
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States

Search clinical trials for: SyB P-1501 placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations